SEARCH

SEARCH BY CITATION

References

  • 1
    Atkinson M, Nordin BE, Sherlock S. Bone disease in obstructive jaundice. Q J Med 1956; 25: 299-312.
  • 2
    Kehayoglou AK, Holdsworth CD, Agnew JE, Whelton MJ, Sherlock S. Bone disease and calcium absorption in primary biliary cirrhosis with special reference to vitamin-D therapy. Lancet 1968; 715-718.
  • 3
    Eastell R, Dickson ER, Hodgson SF, Wiesner RH, Porayko MK, Wahner HW, et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. HEPATOLOGY 1991; 14: 296-300.
  • 4
    Lindor KD, Janes CH, Crippin JS, Jorgensen RA, Dickson ER. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? HEPATOLOGY 1995; 21: 389-392.
  • 5
    Menon KV, Angulo P, Weston S, Dicson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-323.
  • 6
    Hodgson SF, Dickson ER, Wahner HW, Johnson KA, Mann KG, Riggs BL. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann Intern Med 1985; 103: 855-860.
  • 7
    Pereira SP, Bray GP, Pitt PI, Li F, Moniz C, Williams R. Non-invasive assessment of bone density in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11: 323-328.
  • 8
    Crosbie OM, Freaney R, McKenna MJ, Hegarty JE. Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif Tissue Int 1999; 64: 295-300.
  • 9
    Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106: 1284-1290.
  • 10
    Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83: 97-102.
  • 11
    Floreani A, Chiaramonte M, Giannini S, Malvasi L, Lodetti MG, Castrignano R, et al. Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study of calcitonin treatment. J Hepatol 1991; 12: 217-223.
  • 12
    Guanabens N, Pares A, Monegal A, Peris P, Pons F, Alvarez L, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after two years. Gastroenterology 1997; 113: 219-224.
  • 13
    Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis for primary biliary cirrhosis: a randomized trial. J Hepatol 2000; 33: 878-882.
  • 14
    Shiomi S, Masaki K, Habu D, Takeda R, Nishiguchi S, Kuroki T, et al. Calcitriol for bone loss in patients with primary biliary cirrhosis. J Gastroenterol 1999; 34: 241-245.
  • 15
    Nishiguchi S, Shimoi S, Kurooka H, Tamori A, Habu D, Takeda T, et al. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis. J Hepatol 2001; 35: 543-45.
  • 16
    Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am J Gastroenterology 2003; 98: 889-892.
    Direct Link:
  • 17
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Heart and Estrogen/progestin Replacement Study Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy: The Heart and Estrogen/progestin Replacement Study Follow-Up (HERS II). JAMA 2002; 288: 49-57.
  • 18
    Rossow JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
  • 19
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712.
  • 20
    Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous biphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998; 4: 404-409.
  • 21
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-1199.
  • 22
    Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98: 2268-2274.
  • 23
    Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. HEPATOLOGY 1989; 10: 1-7.
  • 24
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging 2000; 12: 1-12.
  • 25
    The Alendronate Once-Weekly Study Group. Two-year results of a once-weekly administration for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002; 17: 1988-1996.
  • 26
    Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, Dickson ER. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999; 19: 115-121.
  • 27
    Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998; 128: 793-800.
  • 28
    Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999; 14: 1614-1621.
  • 29
    Raisz LG, Kream BE, Lorenzo JA. Metabolic bone disease. In: LarsenPR, KronenbergHM, MelmedS, PolonskyK, editors. Williams Textbook of Endocrinology. 10th ed. Philadelphia: WB Saunders, 2002.
  • 30
    Ravn, P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 1999; 24: 237-244.
  • 31
    Watts NB, Becker P. Alendronate increases spine and hip bone mineral density in women with post-menopausal osteoporosis who failed to respond to intermittent cyclical etidronate. Bone 1999; 24: 65-68.
  • 32
    Vittinghoff E, Shlipak MG, Varosy PD, Furberg CD, Ireland CC, Khan SS, et al. Heart and Estrogen/progestin Replacement Study Research Group. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003; 138: 81-89.
  • 33
    Hosking D, Adami S, Felsenberg D, Andia JC, Valimaki M, Benhamou L, et al. Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomized, placebo-controlled study. Curr Med Res Opin 2003; 19: 383-394.
  • 34
    Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass. Results of the FOSIT study. Osteoporos Int 1999; 9: 461-468.
  • 35
    Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC, Adami S, et al. Prevention of non-vertebral fractures by alendronate. A meta-analysis. JAMA 1997; 277: 1159-1164.
  • 36
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002; 112: 281-289.
  • 37
    Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metab 2000; 85: 231-236.
  • 38
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002; 87: 1586-1592.
  • 39
    Guanabens N, Pares A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, et al. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J Bone Miner Res 1998; 13: 731-738.
  • 40
    Chesnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnson CC, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997; 105: 80-81.
  • 41
    DeGroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021.
  • 42
    Ribeiro A, DeVault KR, Wolfe JT, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc 1998; 47: 525-528.
  • 43
    Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. United Kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract 1998; 48: 1161-1162.
  • 44
    Marshall JK, Rainsford KD, James C, Hunt RG. A randomized controlled trial to assess alendronate-associated injury of the upper gastrointestinal tract. Aliment Pharmacol Ther 2000; 14: 1451-1457.
  • 45
    Lanza F, Rack MF, Simon TJ, Lombardi A, Reyes R, Suryawanshi S. Effects of alendronate on gastric and duodenal mucosa. Am J Gastroenterol 1998; 93: 753-757.
    Direct Link:
  • 46
    Graham DY, Malaty HM. Alendronate gastric ulcers. Aliment Pharmacol Ther 1999; 13: 515-519.
  • 47
    Lanza F, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, et al. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 2000; 95: 3112-3117.
    Direct Link:
  • 48
    Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, et al. Upper gastrointestinal tract safety profile of alendronate. Arch Intern Med 2000; 160: 517-525.
  • 49
    Halabe A, Lifschitz BM, Azuri J. Liver damage due to alendronate. N Engl J Med 2000; 343: 365-366.
  • 50
    Lieverse RJ. Hepatitis after alendronate. Neth J Med 1998; 53: 271-272.